商標ウォッチ

公開日2025-08-06
公報種別公開国際商標公報
国際登録番号1858535
国際登録日2025-03-26
区分第5類(薬剤),第10類(医用機器)
商品役務Pharmaceutical preparations; pharmaceutical preparations for injection; pharmaceutical preparation for subcutaneous injection; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations intended to block growth hormone.,Devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; devices for administration of pharmaceuticals for the treatment of tumours; devices for administration of pharmaceuticals for the treatment of carcinoid tumours; devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of esophageal bleeding; devices for administration of pharmaceuticals for metabolic disorders; devices for administration of pharmaceuticals for the treatment of acromegaly; devices for administration of pharmaceuticals for the treatment of polycystic liver disease; devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for the treatment of metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens for administration of pharmaceuticals for the treatment of tumours; pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens for administration of pharmaceuticals for metabolic disorders; pens for administration of pharmaceuticals for the treatment of acromegaly; pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens for administration of pharmaceuticals intended to block growth hormone; devices for subcutaneous administration of pharmaceuticals; devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of injection fluids; devices for injection of injection depot; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; pens for subcutaneous administration of pharmaceuticals; pens for parenteral administration of pharmaceuticals; pens for injection of pharmaceutical depots; pens for subcutaneous injection of pharmaceutical depot; pens for parenteral injection of pharmaceutical depot; pens for injection of injection fluids; pens for injection of injection depot; pens for injections; pens for medical uses.
基礎出願番号019093669
基礎出願日2024-10-21
基礎出願国EM
出願人Camurus AB
OCRテキスト
OCRテキスト2
OCRについて

関連商標